Evidence map›Paper›PMID 39312110›Full record

ArticleBreast cancer (Tokyo, Japan)2024

Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy.

Yuka Endo, Haruru Kotani, Nobuko Tamura, Kiyo Tanaka, Chiho Kudo, Masataka Sawaki, Masaya Hattori, Akiyo Yoshimura, Ayumi Kataoka, Kazuki Nozawa and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yuka EndoDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan. y.endo@aichi-cc.jp.ORCID http://orcid.org/0000-0002-8415-3885
Haruru KotaniDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Nobuko TamuraDepartment of Breast and Endocrine Surgery, Toranomon Hospital, Minato, Tokyo, Japan.
Kiyo TanakaDepartment of Breast and Endocrine Surgery, Toranomon Hospital, Minato, Tokyo, Japan.
Chiho KudoDepartment of Clinical Trial, Aichi Cancer Center Hospital, Nagoya-Shi, Aichi-Ken, Japan.
Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Masaya HattoriDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Akiyo YoshimuraDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Ayumi KataokaDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Kazuki NozawaDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Yuri OzakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Ayaka IsogaiDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Rie KomakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Akira NakakamiDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Nari KureyamaDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Maho KusudoDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Waki HosodaDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya-Shi, Aichi-Ken, Japan.
Hidetaka KawabataDepartment of Breast and Endocrine Surgery, Toranomon Hospital, Minato, Tokyo, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTailored axillary surgery (TAS) is a new approach for selective removal of metastatic lymph nodes. This study evaluated the safety and utility of TAS using a breast biopsy clip inserted into a metastatic lymph node and a point marker consisting of a short hook wire and nylon thread to remove the clipped lymph node.

methodsPatients with breast cancer and clinically confirmed metastases to one-to-three axillary lymph nodes were included in this study. A breast biopsy clip was inserted into the metastatic lymph nodes before neoadjuvant chemotherapy. TAS was performed in patients with ycN0 disease after neoadjuvant chemotherapy. The lymph nodes containing the clips were removed using a point marker. The success criteria for TAS were the removal of the lymph node into which the clip was inserted using a point marker and the identification of the sentinel lymph node. The false-negative rate was calculated for cases in which TAS and axillary lymph node dissection were performed.

resultsThirty individuals from two institutions were enrolled between May 2021 and November 2022, of whom 20 underwent TAS. Ten patients had clinically positive axillary lymph nodes and underwent axillary lymph node dissection. No adverse events were observed in any patient using the clips or point markers. TAS was successful in 18 of the 20 patients (90%). Seven patients underwent TAS and axillary lymph node dissection with a false-negative rate of 0%.

conclusionThe use of clips and point markers to perform TAS is clinically feasible.

Indexed as

AxillaBreast NeoplasmsLymphatic MetastasisLymph Node ExcisionNeoadjuvant TherapyAdultAgedBiopsyChemotherapy, AdjuvantFemaleHumansLymph NodesMiddle AgedSurgical InstrumentsAxillary lymph node metastasisEarly breast cancerGuiding-Marker SystemHydroMARKTailored axillary surgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.